D
Didier Samuel
Researcher at Université Paris-Saclay
Publications - 716
Citations - 38221
Didier Samuel is an academic researcher from Université Paris-Saclay. The author has contributed to research in topics: Liver transplantation & Transplantation. The author has an hindex of 93, co-authored 669 publications receiving 33585 citations. Previous affiliations of Didier Samuel include University of Paris-Sud & South University.
Papers
More filters
Journal ArticleDOI
Antiviral treatment of recurrent hepatitis C after liver transplantation: the need for a multifaceted approach.
TL;DR: It has been shown that patients with cirrhosis awaiting liver transplantation with sustained virological response (SVR) will not develop HCV recurrence, and it appears important to offer antiviral therapy to liver transplant recipients at the risk of severe recurrence of chronic hepatitis C.
Journal ArticleDOI
A Randomized Multicenter Study Comparing a Tacrolimus-Based Protocol with and without Steroids in HCV-Positive Liver Allograft Recipients
Ulf Neumann,Didier Samuel,Pavel Trunecka,Jean Gugenheim,Giorgio Enrico Gerunda,Styrbjörn Friman +5 more
TL;DR: Results are inconclusive due to the unexpected lower completion rates in the TAC/DAC arm, and Steroid-free immunosuppression had no real impact on HCV viral load.
Journal ArticleDOI
Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine.
Federico G. Villamil,Gary A. Levy,Gian Luca Grazi,Sérgio Mies,Didier Samuel,F. Sanjuan,Massimo Rossi,John R. Lake,S. Munn,F. Mühlbacher,L. Leonardi,U. Cillo +11 more
TL;DR: Choice of calcineurin inhibitor may be a contributing factor to deteriorating patient and graft survival following liver transplantation for hepatitis C virus (HCV) and Tacrolimus may be associated with increased risk of histological HCV disease recurrence compared to cyclosporine.
Journal ArticleDOI
Acute Liver Failure/Injury Related to Drug Reaction With Eosinophilia and Systemic Symptoms: Outcomes and Prognostic Factors.
Philippe Ichai,Astrid Laurent-Bellue,Faouzi Saliba,D. Moreau,Camille Besch,Claire Francoz,Laurence Valeyrie-Allanore,Sylvie Roussin Bretagne,M Boudon,Teresa Antonini,Florent Artru,Gabriella Pittau,Olivier Roux,Daniel Azoulay,Eric Levesque,François Durand,Catherine Guettier,Didier Samuel +17 more
TL;DR: The spontaneous prognosis of patients with sALI/ALF due to DRESS is poor and was not improved by corticosteroid therapy and dynamic variables regarding factor V values are predictive of a poor outcome.
Journal ArticleDOI
Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment‐naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)
Stefan Zeuzem,Robert Flisiak,John M. Vierling,W. Mazur,Giuseppe Mazzella,Satawat Thongsawat,D. Abdurakhmanov,N. Van Kính,P. Calistru,J. Heo,C. Stanciu,Michael K. Gould,M. Makara,S.-J. Hsu,Peter Buggisch,Didier Samuel,David Mutimer,B. Nault,Michael Merz,W. Bao,Louis Griffel,Clifford A. Brass,Nikolai V. Naoumov +22 more
TL;DR: Alisporivir is an oral, host‐targeting agent with pangenotypic anti‐hepatitis C virus (HCV) activity and a high barrier to resistance.